Abstract Library

#4625 Efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with neuroendocrine neoplasms – A systematic review and experience from NETwerk, a Belgian ENETS Center of Excellence

Introduction: Current treatment guidelines remain inconclusive due to scarcity of data regarding the optimal systemic treatment for metastatic gastroenteropancreatic (GEP) neuroendocrine tumours (NET) grade 3 and aggressive GEP-NET grade 2. Similarly, for metastatic pulmonary typical (TC) and atypical carcinoids (AC), the indication for chemotherapy is unclear. Recent evidence highlights a promising role for CAPTEM, combining temozolomide (TEM) with capecitabine (CAP), showing encouraging antitumoural activity and safety profiles for these indications.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Lambrechts C, Islam O, de Weerdt C, Verbruggen L,

Keywords: capecitabine, temozolomide, CAPTEM, GEP-NET, pulmonary NEN, safety, efficacy, systematic review,

#4391 Clinicopathologic characteristics, therapy and outcomes of gastroenteropancreatic neuroendocrine tumours: A single-centre experience

Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are tumours derived from neuroendocrine cells that can occur anywhere along the gastrointestinal tract and comprise a heterogeneous family of neoplasms with a wide and complex spectrum of clinical behaviour.

Conference:

Presenting Author:

Authors: Behourah Z, Ahed Messaoud M, Hamidatou K, Megaiz A, Lechar M,

Keywords: Gastroenteropancreatic neuroendocrine tumour, Functional neuroendocrine tumour, Somatostatin analogue (SSA), Chemotherapy,

#4367 Comparative analysis of post-pancreatic surgical complications in elderly versus younger patients with inactive neuroendocrine pancreatic tumours

Introduction: The management of small, asymptomatic non-functional pancreatic neuroendocrine neoplasms (NF-pNENs) is contentious, with two main approaches: surgical resection and "watch-and-wait." Current guidelines recommend monitoring NF-pNENs under 2 cm based on retrospective data, although recent U.S. studies suggest improved survival with surgery for 1-2 cm NF-pNENs. Some suggest the "watch-and-wait" approach for older patients, though its efficacy is unclear.

Conference:

Presenting Author: Zamparas A

Authors: Zamparas A, Aghamaliyev U, Seidel G, Meyer Y, Werner J,

Keywords: nf-pnen, popf, pancreatic surgery, pNEN, pancreas,

#4346 Efficacy and safety of surufatinib in the treatment of thymic neuroendocrine tumours: A 102-case retrospective study

Introduction: The SANET-ep study confirmed that patients with non-pancreatic NET could benefit from surufatinib treatment compared with placebo. However, there is a lack of sufficient retrospective data on surufatinib’s efficacy in treating thymic neuroendocrine tumours (TNETs).

Conference:

Presenting Author:

Authors: Jia X, Sun Z, Xu J, Huang D, Chen F,

Keywords: neuroendocrine tumour, thymic, surufatinib, treatment,

#4306 EVENET: Randomised phase II trial of everolimus 5mg vs. 10mg daily in patients with neuroendocrine tumours

Introduction: Everolimus 10mg PO daily is approved for patients (pts) with advanced G1/G2 neuroendocrine tumours (NET) but is associated with significant toxicity, including 20% of serious infections in real-world pts. In phase I trials, 5mg/day was sufficient to inhibit the mTOR pathway. Retrospective data suggest that 5mg/day is similarly effective to 10mg/day but less toxic.

Conference:

Presenting Author:

Authors: Riechelmann R, Campos A, Durant L, Bulzico D,

Keywords: everolimus, neuroendocrine tumour, dose optimisation, toxicity,